Hirudin Hman1
First of five H. manillensis hirudin variants — Liu 2023 demonstrates anticoagulant activity (vs hirudin_Hman3/4 which were inactive).
Preclinical / mechanisticLast updated: 2026-05-28 · Reviewed by ASH Editorial Board
Mechanistic Evidence Box
Preclinical / mechanistic- Page type
- Compound profile
- Evidence type
- First of five H. manillensis hirudin variants — Liu 2023 demonstrates anticoagulant activity (vs hirudin_Hman3/4 which were inactive).
- Evidence level
- In vitro
- Drug vs leech
- Recombinant (genetically expressed)
- Safety domains
- Bleeding
Clinical translation limit
Hirudin Hman1's in vitro anticoagulant activity does NOT establish clinical efficacy. No FDA-approved derivative; H. manillensis is not on the FDA K040187 cleared device species list.
Molecular Profile
- Category
- Anticoagulant
- Evidence tier
- Preclinical
- Molecular weight
- 7,000 Da
- Source species
- Hirudinaria manillensis
- Discovered
- 2023 · Liu Z et al.
Biological Targets
- → thrombin (Factor IIa)
Key Citations
- Liu Z et al. (2023), Genes (Basel) · PMID 38003011
External Resources
Related Anticoagulant Compounds
Hirudin
The most potent natural thrombin inhibitor — and the molecular template for three FDA-approved direct thrombin inhibitor drugs.
Antistasin
Factor Xa inhibitor — prototype molecule that inspired the entire DOAC drug class (rivaroxaban, apixaban).
Ghilanten
Factor Xa inhibitor with anti-metastatic activity in animal cancer models — translational dual-use compound.
Lefaxin
Factor Xa inhibitor with anti-inflammatory properties.